Isolation of Viable Epithelial and Mesenchymal Circulating Tumor Cells from Breast Cancer Patients

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2024 Jan 9

PMID 38194026

Authors

Justyna Topa

Anna J Zaczek

Aleksandra Markiewicz

Affiliations

Soon will be listed here.

Abstract

Circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition (EMT) may exhibit more aggressive features than epithelial CTCs and are more frequently observed during disease progression. Therefore, detection and characterization of both epithelial and mesenchymal CTCs in cancer patients are urgently needed to allow for a better understanding of the metastatic process and more effective treatment. Here we describe a method for detection and isolation of viable epithelial and mesenchymal CTCs from peripheral blood of breast cancer patients. The method is based on density gradient centrifugation, multiplex immunofluorescent staining, and negative anti-CD45 selection. Cells obtained after the procedure are suitable for genomic or transcriptomic profiling, and they can also be isolated by micromanipulation for single-cell analysis.

Citing Articles

Novel Isolating Approaches to Circulating Tumor Cell Enrichment Based on Microfluidics: A Review.

Qiao Z, Teng X, Liu A, Yang W Micromachines (Basel). 2024; 15(6).

PMID: 38930676 PMC: 11206030. DOI: 10.3390/mi15060706.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Dong G, Wang D, Liang X, Gao H, Wang L, Yu X . Factors related to survival rates for breast cancer patients. Int J Clin Exp Med. 2014; 7(10):3719-24. PMC: 4238527. View

Fallahpour S, Navaneelan T, De P, Borgo A . Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open. 2017; 5(3):E734-E739. PMC: 5621954. DOI: 10.9778/cmajo.20170030. View

Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D . Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15(4):406-14. DOI: 10.1016/S1470-2045(14)70069-5. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Markiewicz A, Nagel A, Szade J, Majewska H, Skokowski J, Seroczynska B . Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients. Transl Oncol. 2018; 11(3):722-731. PMC: 6056759. DOI: 10.1016/j.tranon.2018.03.006. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Moreno-Bueno G, Portillo F, Cano A . Transcriptional regulation of cell polarity in EMT and cancer. Oncogene. 2008; 27(55):6958-69. DOI: 10.1038/onc.2008.346. View

10.

Zhang S, Wu T, Peng X, Liu J, Liu F, Wu S . Mesenchymal phenotype of circulating tumor cells is associated with distant metastasis in breast cancer patients. Cancer Manag Res. 2017; 9:691-700. PMC: 5703158. DOI: 10.2147/CMAR.S149801. View

11.

Gao X, Liu X, Lu Y, Wang Y, Cao W, Liu X . PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation. Breast Cancer. 2019; 26(5):663-671. PMC: 6694096. DOI: 10.1007/s12282-019-00966-3. View

12.

Ocana O, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S . Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012; 22(6):709-24. DOI: 10.1016/j.ccr.2012.10.012. View

13.

Markiewicz A, Topa J, Popeda M, Szade J, Skokowski J, Welnicka-Jaskiewicz M . Activation of epithelial-mesenchymal transition process during breast cancer progression - the impact of molecular subtype and stromal composition. Acta Biochim Pol. 2021; 68(3):385-392. DOI: 10.18388/abp.2020_5719. View

14.

Mostert B, Kraan J, Vries J, van der Spoel P, Sieuwerts A, Schutte M . Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat. 2010; 127(1):33-41. DOI: 10.1007/s10549-010-0879-y. View

15.

Zabouo G, Imbert A, Jacquemier J, Finetti P, Moreau T, Esterni B . CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 2009; 11(1):R1. PMC: 2687703. DOI: 10.1186/bcr2215. View

16.

Onstenk W, Kraan J, Mostert B, Timmermans M, Charehbili A, Smit V . Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Mol Cancer Ther. 2015; 14(3):821-7. DOI: 10.1158/1535-7163.MCT-14-0653. View

17.

Strijbos M, Gratama J, Kraan J, Lamers C, den Bakker M, Sleijfer S . Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer. 2008; 98(11):1731-5. PMC: 2410112. DOI: 10.1038/sj.bjc.6604383. View

18.

Guo M, Li X, Zhang S, Song H, Zhang W, Shang X . Real-time quantitative RT-PCR detection of circulating tumor cells from breast cancer patients. Int J Oncol. 2014; 46(1):281-9. DOI: 10.3892/ijo.2014.2732. View